Replies to post #128580 on Biotech Values

[DewDiligence]

REGN sells $460M* of convertible debt on terms to be announced:

http://finance.yahoo.com/news/Regeneron-Pharmaceuticals-prnews-277497583.html?x=0&.v=1

Now is a good time to do it—before investors figure out that Eylea is going to be a commercial dud!

*Assuming exercise of the underwriter’s 15% overallotment option.